D. E. Shaw & Co., Inc. Cabaletta Bio, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
Shares
3 transactions
Others Institutions Holding CABA
# of Institutions
92Shares Held
79.6MCall Options Held
406KPut Options Held
90.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$34.9 Million4.41% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$31.9 Million0.02% of portfolio
-
Jennison Associates LLC8.5MShares$30.7 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.79MShares$24.5 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA5MShares$18.1 Million0.77% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $105M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...